USNA Chief Commercial Officer Brent Neidig Sells $18K of Stock

Brent Neidig, the Chief Commercial Officer of USANA Health Sciences, Inc. (NYSE:USNA), sold 909 shares of the company on June 15, 2026. The shares were sold at an average price of $20.01 each, totaling $18,189.09. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at USANA Health Sciences, Inc.

In addition to Neidig's recent sale, he also sold 1,602 shares on June 12, 2026, at $20.15 each. Other notable insider transactions include Paul Jones, Chief People Officer, who sold 5,561 shares at $18.50 on June 8, 2026, and 6,813 shares at $18.95 on May 28, 2026. John Turman Fleming sold 2,450 shares at $17.93 on June 1, 2026, and Doug Iekking, Chief Financial Officer, sold 5,360 shares at $18.75 on May 27, 2026.

Other Institutional Activity in USANA Health Sciences

Among other institutional investors, BlackRock, Inc. increased its holdings in USANA Health Sciences by 78,415 shares, bringing its total to 1,190,416 shares valued at approximately $20.8 million. On the other hand, Pzena Investment Management LLC reduced its stake by 25,496 shares, now holding 1,108,933 shares worth about $19.4 million. Renaissance Technologies LLC also cut its position by 129,693 shares, ending with 1,017,630 shares valued at $17.8 million. Dimensional Fund Advisors LP trimmed its holdings by 14,229 shares, resulting in 834,223 shares valued at $14.6 million. Meanwhile, Nantahala Capital Management, LLC significantly increased its position by 225,000 shares to 810,074 shares, valued at approximately $14.2 million.

USANA Health Sciences, Inc. Stock Up 34.4%

Shares of USANA Health Sciences are currently trading around $19.01. The company has a market capitalization of about $351 million and a P/E ratio of 38.02, with a forward P/E of 6.86. USANA's stock has experienced a 52-week low of $16.60 and a high of $38.32. The stock's 50-day moving average is $18.72, and the 200-day moving average is $20.94. USANA maintains a current ratio of 2.51 and a quick ratio of 1.47, with a debt-to-equity ratio of 2.35.

Recent Earnings

USANA Health Sciences reported revenue of approximately $925.9 million with a slight growth of 0.3%. The company achieved a net margin of 0.958% and a return on equity of 1.55%. Earnings per share stood at $0.50. The next earnings report is expected on July 21, 2026.

Analysts Set New Price Targets

DA Davidson has maintained a "hold" rating on USANA Health Sciences, with its most recent price target set at $36.00 on February 27, 2025. The consensus among analysts is a "hold" recommendation, with a mean target price of $39.00 based on one analyst's opinion.

About USANA Health Sciences

USANA Health Sciences, Inc. develops, manufactures, and sells nutritional, personal care, and skincare products. It operates in the Asia Pacific, the Americas, and Europe, focusing on core nutritional and direct-to-consumer segments. The company's product lineup includes supplements for various health aspects, meal replacement shakes, and skincare regimens. USANA was founded in 1992 and is headquartered in Salt Lake City, Utah, under the leadership of CEO Kevin G. Guest. With about 1,570 employees, USANA continues to expand its global presence.

Bottom Line

Insider transactions like Brent Neidig's sale provide a glimpse into the activities of company executives and their stock dealings. While these actions are informative, they don't necessarily indicate future performance. Investors often track such movements as part of a broader strategy, recognizing that 13F filings and insider trades reflect past actions rather than current positions.